Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957521 | 0.83 | KMT2A (0.53) | KMT2AMEN1USP2TSHRMAPK1 | |
| SCHEMBL5957454 | 0.83 | KMT2A (0.51) | KMT2AMEN1USP2TSHRMAPK1 | |
| SCHEMBL5957350 | 0.82 | TRPA1 (0.55) | KMT2AMAPK1SMN1; SMN2LMNAMAPT | |
| SCHEMBL5957420 | 0.82 | TRPA1 (0.66) | MAPK1TP53TRPA1 | |
| SCHEMBL5957447 | 0.77 | TRPA1 (0.66) | USP2LMNAMAPTPOLBHTT | |
| SCHEMBL6234824 | 0.76 | TRPA1 (0.49) | KMT2AMEN1TSHRSMN1; SMN2LMNA | |
| SCHEMBL5957829 | 0.73 | TRPA1 (0.60) | MAPTTRPA1HPGD | |
| SCHEMBL7097607 | 0.71 | MAPT (0.68) | KMT2AMEN1USP2MAPTPOLB | |
| SCHEMBL7171065 | 0.71 | MAPT (0.57) | KMT2AMEN1USP2MAPTPOLB | |
| SCHEMBL5957816 | 0.71 | MMP13 (0.48) | KMT2AMEN1TSHRMAPK1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040957-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040957-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP25, MMP15 | KMT2A 3012/4885MEN1 4045/4885USP2 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.